The Role of the Thomsen-Friedenreich Antigen As a Tumor-Associated Molecule

by Wolfgang Dippold,* Andrea Steinborn,* and Karl-Hermann Meyer zum Büschenfelde*

The Thomsen-Friedenreich antigen (Gal-GalNAc) represents a tumor-associated molecule, which is assumed to be one of the few chemically well-defined antigens with a proven association with malignancy. In order to analyze the role of the carbohydrate structure Gal-GalNAc for gastrointestinal tumors, we immunized Balb/c mice with MCF-7 breast tumor cells together with synthetic Gal-GalNAc linked to a BSA carrier. One monoclonal antibody (82-A6) was established which recognizes the Thomsen-Friedenreich antigen according to the biochemical and serological analysis presented here. In contrast to the studies performed in the past, immunohistochemical results using this antibody 82-A6 did not exhibit a reactivity clearly restricted to tumors. Preliminary biochemical analysis revealed that the T-determinant is detectable in the high-molecular weight range (about 1000 kD), suggesting that the Gal-GalNAc epitope is found on mucinlike glycoproteins. Tumor restriction of Thomsen-Friedenreich antigen may therefore be determined either by the protein backbone or by the β-glicosidic linkage of the carbohydrate structure to the protein.

Introduction

During carcinogenesis, alterations occur in the biosynthesis of carbohydrate structures on the cell surface. Therefore, carbohydrates linked either to proteins or lipids are recognized as tumor-associated molecules (1,2). An interesting novel approach to achieve tumor immunity is to vaccinate patients with chemically synthesized glycopeptides that are restricted to tumors. Several investigators (3,4) have succeeded in generating glycopeptides with Gal-GalNAc residues coupled to serine or threonine and bound to a carrier protein. This structure has long been known as the Thomsen-Friedenreich antigen (T-antigen) (5). The T-antigen was extensively studied by Springer and his colleagues (6) and believed to be tumor restricted. This antigen is the immediate precursor of the human blood group MN antigens, which are located in the NH2-terminal region of the major sialglycoprotein (glycophorin A) of human erythrocytes. The immunodominant group of the T-antigen [βGal (1-3) αGalNAc] is described as a cryptic determinant on human erythrocytes, which is exposed by neuraminidase treatment. This unmasked form has been reported to be present on most human carcinomas.

Although it has been assumed that the tumor-associated structure is immunologically similar to the T-antigen expressed on desialylated red blood cells, no one has yet defined the precise carbohydrate group or characterized the molecule carrying the T-antigen determinant on carcinomas. Therefore, we have tried to establish a monoclonal antibody specific for T-antigen.

Results

An Antibody with Gal-GalNAc Specificity

By immunizing mice with the cultured tumor breast cell line MCF-7 together with a synthetic, chemically synthesized carbohydrate hapten [βGal (1-3) αGalNAc-serine + threonine] linked to a BSA carrier (bovine serum albumin), we succeeded in generating a monoclonal antibody (82-A6, IgM subclass) with T-specificity. Fusion products of spleen cells and cells of the mouse myeloma cell line P3-NS1/Ag 4-1 were grown in selective media as previously described (7). The supernatants were screened for antibody production, and clones were selected on the basis of anti-T reactivity. One clone (mAb 82-A6) was shown to bind to asialoglycoporin, but not to glycoporin, both of which were obtained from Biocarb (Lund, Sweden). Moreover, the antibody reacted with the purified asialglycoproteins of both the MM and NN blood groups. These asialglycoproteins differ in the polypeptide chain only.

To make sure that 82-A6 binding to asialoglycoporin is dependent on the carbohydrate residues of the erythrocyte membrane protein, the purified protein was exposed to NaBH4 in alkaline solution to separate the O-glycosidically linked Gal-GalNAc side chains from the
protein backbone. MAb binding to asialoglycophorin was abolished after NaBH₄ treatment.

Reactivity of the monoclonal antibody was studied by ELISA assays of glycoproteins bound to polystyrene microtiter plates. An additional inhibition assay using asialo-glycophorin as the target antigen was performed to confirm the results obtained by these direct tests and yielded the same results.

Further analysis included reactivity of mAb 82-A6 with asialo-neuraminidase-treated red blood cells. Hemagglutination was obtained with desialylated red blood cells up to a titration end point of 200 ng/mL mAb 82-A6. Agglutination of untreated red blood cells occurred only at very high antibody concentrations and with an incubation period of at least 5 min. Table 1 summarizes the epitope analysis of a mAb 82-A6, demonstrating that the structure recognized represents the T-antigen.

**Reactivity of Anti-T mAb with Human Tissues**

To determine the tissue reactivity of the mAb 82-A6, normal and malignant tissues were tested as summarized in Table 2. Cryostat sections of frozen specimens were collected on glass slides, air dried, and stained by the indirect immunoperoxidase method. MAb 82-A6 did not show any tumor restriction and stained normal and tumor epithelial tissues equally well. The antibody also reacted with the majority of cultured human tumor cell lines. In addition to well-known T-positive tumor cell lines, binding sites for anti-T mAb were also found on one of three melanomas. Normal peripheral blood mononuclear cells (PBLs) did not express the T-antigen using mAb 82-A6 by FACS analysis (fluorescent-activating cell sorting). T-antigen was not revealed even after treating PBLs with neuraminidase.

**Molecular Weight of T-Antigen-Carrying Proteins**

Solubilized proteins of the human breast tumor cell line CAMA were applied to a molecular weight exclusion column (Superose 6, Pharmacia, Uppsala, Sweden). Eluted proteins were tested for 82-A6 binding and detected in the high molecular weight fractions of about 1000 kD size. These results suggest that the T-specific carbohydrate epitope is expressed on mucinlike glycoproteins.

**Conclusions**

In this paper we describe a monoclonal antibody that was generated following immunization of Balb/c mice with a human tumor cell line known to express high amounts of T-antigen together with a chemically synthesized T-structure. The epitope recognized by mAb 82-A6 has been identified as T-antigen on the basis of its reactivity with asialoglycophorin but not glycophorin, its inability to bind deglycosylated asialoglycophorin, and the results of hemagglutination tests with neuraminidase-treated red blood cells.

It appears noteworthy, however, that agglutination of untreated red blood cells also occurred at very high antibody concentrations and after longer incubation periods, which has neither been tested nor observed with any other anti-T antibody. The antibody we describe...
here reacts with the Gal-GalNAc structure, which is linked by an α-glycosidic bond to serine and threonine. Longenecker et al. have used a panel of α- and β-glycosidically linked Gal-GalNAc structures bound to carrier proteins for immunization (4). Their results indicate that only by immunization with the β-glycosidically linked disaccharide, and not with the α-glycosidically linked one, was an mAb with some tumor restriction obtained. These findings are compatible with our own results. Several other investigators have described anti-T mAb (9–12). In no case, however, has there been a detailed immunohistochemical analysis to show that the antibodies are tumor restricted. Immunohistochemical studies with mAb 82-A6 revealed that T-antigen is not restricted to malignant tissues but is also found in high amounts on normal tissues. These results suggest that tumor restriction is either determined by the β-glycosidic linkage or depends on the protein backbone as indicated by studies of Schlom and his colleagues of the tumor antigen B72.3 (13).

The role of α- or β-glycosidic linkage in relation to tumor association will only be clarified when synthetic carbohydrate structures with definitively known α- or β-linkage to carrier proteins are available. Up to now this has not been the case. Nevertheless, the antibody and the test systems established so far may be useful reagents to detect the real T-antigen, which has a terminal Gal-GalNAc residue.

This work was supported by a Grant from the Deutsche Forschungsgemeinschaft, SFB 302, project C-4.

REFERENCES

1. Hakomori, S. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res. 45: 2405–2414 (1985).

2. Feizi, T. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature 314: 53–57 (1985).

3. Kunz, H., Birnbach, S. Synthese von O-Glycopeptiden des tumormasozierten Tn- und T-Antigen-Typs und deren Anknüpfung an Rinderserumalbumin. Angewandte Chemie 98: 354–355 (1986).

4. Longenecker, B. M., Williams, D. J., Mac Lean, G. D., Selvaraj, S., Suresh, M. R., and Joujaim, A. Monoconal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers. JNCI 78: 489–496 (1987).

5. Uhlenbruck, G. The Thomsen-Friedenreich (TF) receptor: an old history with new mystery. Immunol. Commun. 10: 251–264 (1981).

6. Springer, G. F. T and Tn, general carcinoma autoantgens. Science 224: 1198–1205 (1984).

7. Dippold, W., Lloyd, K. O., Li L. T. C., Ikeda, H., Oettel, H. F., Old, L. J. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with monoclonal antibodies. Proc. Natl. Acad. Sci. USA 77: 6114–6118 (1980).

8. Dippold, W., Bernhard, H., Klingel, R., Dienes, H. P., Kron, G., Schneider, B., Knuth, A., Meyer zum Büschenfelde, K.-H. A common epithelial cell surface antigen EPM-1 on gastrointes- tinal tumors and in human sera. Cancer Res. 47: 3873–3879 (1987).

9. Clausen, H., Stroud, M., Parker, J., Springer, G., Hakomori, S. Monoclonal antibodies to the blood group A associated structure galactosyl-A: specificity and relation to the Thomsen-Friedenreich antigen. Mol. Immunol. 24: 199–204 (1988).

10. Metcalfe, S., Springer, G. F., Svvennsen, R. J., Tegtmeier, H. Monoclonal antibodies specific for human Thomsen-Friedenreich T and Tn blood group precursor antigens. In: Protides of the Biological Fluids, Vol. 32 (H. Peeters, Ed.), Pergamon Press, Oxford, 1985, pp. 759–765.

11. Rahman, A. F. R., Longenecker, B. M. A monoclonal antibody specific for the Thomsen-Friedenreich cryptic T-antigen. J. Immunol. 129: 2021–2024 (1982).

12. Stein, R., Chen, S., Grossman, W., Goldberg, D. M. Human lung carcinoma monoclonal antibody specific for the Thomsen-Friedenreich antigen. Cancer Res. 49: 32–37 (1989).

13. Johnson, V. G., Schom, J., Paterson, A. J., Bennett, Jr., Magnani, J. L., Colcher, D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res. 46: 850–857 (1986).